New Evidence on Cardiotoxicity in AML Treatment A comprehensive new systematic review analyzed 41 studies involving 5,995 patients with acute myeloid leukemia (AML) who received anthracycline-based regimens during remission induction. The pooled rate of heart failure in this population was 3.2%, with notable differences depending on the anthracycline used: 2.3% with daunorubicin, 5.0% with idarubicin,…